436 Studies Now Enrolling
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Patients with Progressive Supranuclear Palsy with an Open-Label Extension
A study of safety and efficacy of IV BMS-986168 in patients with Progressive Supranuclear Palsy.
| Sponsor: | Biogen |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAR2560 |
| U.S. Govt. ID: | NCT03068468 |
| Contact: | Evelyn Dominguez-Rivera: 212 -305 -2371 / edd5@cumc.columbia.edu |
Additional Study Information:
The Primary objective of the study is to evaluate the efficacy of the study drug, compared to placebo, as measured by a change from baseline in the PSP Rating Scale (PSPRS) after one year, and to assess the safety and tolerability of the study drug, relative to placebo.
This study is closed
